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Abstract
Fatty acid binding proteins (FABPs) are an evolutionarily conserved intracellular lipid binding protein family which facilitates 
lipid transport, metabolism and responses inside cells. Emerging evidence suggests dysregulated lipid metabolism and signalling 
may result in development of diseases and cancer. In this review, we described the FABP family proteins and summarised their 
association with different diseases. We have also described role of each FABP member played in development and malignant 
dissemination of different types of cancers.
Introduction
Fatty acid-binding proteins (FABPs) are a group of molecules 
playing important roles in lipid transportation. FABPs are expressed 
in different configurations in numerous tissues and have diverse 
functions [1]. Transportation of fatty acids into cells is achieved 
either through membrane diffusion or via help of receptors like 
G-protein. FABPs act as a chaperone regulating all functions of cell 
lipid transportation and storage. Inside cells, FABPs send lipid to 
endoplasmic reticulum for signalling, to mitochondria for oxidative 
process, and to nucleus for transcription activity. All members of 
FABPs can bind long chain fatty acids, however; they differ in their 
selectivity, affinity and binding mechanism [2]. It is clear that the 
roles of FABPs are various and include the transportation of fatty 
acids to cells, participating in PPAR signal transduction, regulating 
enzyme activity, and controlling gene expression and cell growth. 
FABP family members are small protein molecules weighting from 
14,208 (FABP2) to 15,565 Delton [3].
In humans, FABPs are classified as part of the intracellular lipid 
binding protein family. Since FABP10 and FABP11 are not seen in 
humans, and are expressed only in other species, such as zebrafish 
(Danio Rerio) and teleost fish (Solea senegalensis) [4, 5], this protein 
family is made up of 10 members: FABP1 to FABP9, and FABP12. 
Like other lipid metabolism factors, FABPs had been thought to 
be involved in transportation of lipids only until their importance 
 
in cancer pathogenesis was recognized with the findings of their 
differential expression patterns in cancer tumorigenesis and 
progression [4, 6]. The various actions of adipocytes, fatty acids 
and proteins in cancer progression have been revealed. Their roles 
range from being utilized as energy providers and cell signalling 
molecules to the regulations of cancer metabolisms, hence, to 
promote more aggressive cancer phenotypes by enabling the 
cancer cell relocation, infiltration, and self-renewal [7]. The degree 
of involvement of different FABPs in malignant progression of 
cancer cells varies from playing a crucial role to a non-direct role. 
FABP1
FABP1 is found mainly in the liver. It is also present in 
smaller amounts in intestines, kidneys and the stomach. Several 
ligands can bind to FABP1 to achieve its significant functions of 
cellular activities. Ligands include a variety of fatty acids and 
their metabolites to bilirubin and heme [8]. FABP1 has a proven 
relation to steatotic liver and non-alcoholic fatty liver disease. The 
down regulation of FABP1 activates the quiescent stellate cells in 
the liver leading to the secretion of collagen and proteins by the 
stellate cells and the subsequent hepatic fibrogenesis [4, 9]. Some 
studies were performed to find out whether FABP1 was related to 
cancer in organs it localised, such as Liver, intestine and Kidney. 
At least one study reported an association between FABP1 and 
Citation: Xi Jin, Asmaa Al-Bayati, Gang He, Jiacheng Zhang, Qiang Wei, Youqiang Ke*. Fatty Acid-Binding Proteins and Their Roles in Disease 
and Cancer. Open Acc J Oncol Med 5(1)- 2021. OAJOM.MS.ID.000204. DOI: 10.32474/OAJOM.2021.05.000204
                                                                                                                                                          Volume 5 - Issue 1 Copyrights @ Youqiang Ke, et al.Open Acc J Oncol Med
525
colon cancer; significant downregulation of FABP1 was found in 
circulating colon cancer cells [10]. Loss of FABP1 was identified 
as a major contributing factor to microsatellite unstable colorectal 
carcinomas [4, 11]. These studies seemed to suggest that FABP1 
may be a tumour suppressor. In contrast, another study on the 
role of FABP1 in hepatocellular carcinomas (HCC) suggested 
that FABP1 may have a tumour promoting role. FABP1 induced 
vascular endothelial growth factor (VEGF) expression through its 
interaction with the VEGF receptor, leading to new blood vessels 
formation (angiogenesis). This investigation showed that the role 
of FABP1 in enhancing migration properties of the cancer cells via 
the VEGFR2 pathway, indicating a promoting role of FABP1 in the 
metastasis of HCC [12]. FABP1 was found to be highly upregulated 
in the HCC cells. The increased level of FABP1 was correlated to 
lymph node metastasis and the stage of the malignant progression 
[4, 13]. Further investigations are needed for a clear understand of 
the exact role of FABP1 in cancer development Table 1. 
Table 1:
Criterion WOMAC KOOS OKS
Length 24 items: 5 pain, 2 stiffness, 17 function [14].
Length 42 items: 9 pain, 5 symptoms, 
17 ADL difficulty, 5 sport, recreation 
and quality of life [5].
Short, 12 items: 5 pain, 7 
function [4].
Origin date 1982 1998 evaluation for knee injury & OA [5]. 1998 for TKA outcome [4].
Validity for TKA
Construct validity showed moderate to strong 
correlation with other measurements post-TKA 
(SF36, Nottingham health profile function scale, 
range of motion, radiology Kellgren rating) and 
disability scale [9].
Construct validity shows high correla-
tion between KOOS & SF36. Rs=.62 
pain, .48 ADL. Low correlation with 
mental scores (convergent validity) 
[7].
Construct validity shows 
moderate correlation pre-
TKA with American knee 
society (AKS); significant 
agreement with SF36 & 
HAQ [4].
Sensitivity/ responsiveness
Response rate at one year 90%
Significant improvement, p<.001, 
effect size for quality of life 2.86–3.54 
at 6/12 months, pain 2.28–2.55 at 
6/12 months, sport 1.18–1.08 at 6/12 
months, respectively [7].
Effect size 2.19, larger than 
SF36 [4].
Effect size 2.25 [8].
Reliability for TKA
Acceptable ≥ .70 internal reliability for pain 
and stiffness, excellent ≥ .90-.95 for function. 
Test-retest reliability acceptable for pain and 
function, weak for stiffness (11). Correlation 
coefficients for pain, function and overall score 
0.55, 0.50 and 0.55, respectively [13].
ICC post-TKA 0.75 with no significant 
changes between two measures [7].
Internal consistency: Cron-
bach’s alpha .87 pre-TKA 
and .93 6 months post.
Test-retest: r=.92, ± 0–4 
points of differences [4].
Time required 11 minutes 10 minutes [5] 5 minutes
Accepted missing values Not more than 5 pain, 2 stiffness, 4 function [14].
Two–six items and substituted by 
average value for dimensions [6, 7]. 2 items
Outcome categories
Improvement in pain & function ≥ 50% & abso-
lute change ≥ 20. Responder if pain/ function/ 
global ≥ 20%, absolute ≥ 10.
0–100: 0 extreme knee problems, 100 
no knee problems.
Excellent >41, Good 34–41, 
Fair 27–33, Poor < 27. [4].
MCID* 15 points [14]. 8–10 points [5], 6-9 points [16]
5 points for 2 groups’ 
estimations, 9, 7 points for 
cohorts & individuals [2,12].
Floor effect 14%. 48% for sport & recreation section [1,7] 7% (1), no effect [15]
Ceiling effect
6 MONTHS: 27% for pain, 51% for stiffness 
[10];
6 MONTHS: 15% for pain, 16% for 
sport, 6 MONTHS: 5–14%; 12 
MONTHS: 7–22% (1), no 
effect [15].12 MONTHS: 17% quality of life, 30% pain, 
64% stiffness [10].
12 MONTHS: 22% pain & 17% for 
quality of life [1, 7].
FABP2
FABP2, also known as intestinal fatty acid binding protein, is 
expressed exclusively in the small intestine, in which dietary lipids 
are absorbed. The part of the small intestine with highest levels of 
FABP2 is the jejunum. Saturated and unsaturated fats are known to 
be used for the triglyceride synthesis. When excessive fatty acids 
accumulate, FABP2 controls fatty acid transferring in order to 
prevent the alteration of membrane characteristics by un-esterified 
fatty acids build up [4]. A number of FABP2 polymorphism studies 
were carried out and revealed clues of the roles it has in the human 
intestine. A threonine substitution at amino acid 54 was identified 
and it resulted in disturbed lipid metabolism. Increased insulin 
resistance, hypertriglyceridemia and increased accumulation of 
triglycerides were described in the threonine variant [4]. FABP2 is 
related to the occurrence of certain diseases, some of which may 
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progress to the development of cancers. These diseases include 
diabetes, myocardial infarction, stroke, and gallbladder diseases 
[14]. Very few studies were carried out to detect the role of FABP2 in 
cancer progression. However, there is at least one study conducted 
in 2010 to investigate the association of FABP2 expression with 
dietary habits and lipid uptake in colorectal carcinoma. This study 
drew the attention to the negative correlation between FABP2 and 
fat uptake. Therefore, FABP2 is unlikely to be an accurate predictor 
of the risk of colorectal cancer [15].
FABP3
FABP3 is expressed predominantly in the heart and muscle 
tissue, as well as the tissue of the lung, ovary, brain, placenta, 
mammary gland, and stomach [8]. In order to provide enough energy 
to these tissues with high energy expenditures, FABP3 transfers 
fatty acids to mitochondria to produce energy. However, elevated 
levels of FABP3 may evoke cardiac dysfunction by reducing calcium 
level in the sarcoplasmic reticulum [16]. FABP3 accumulates in 
the brain tissue 10-fold more than the brain FABP [FABP7]. This 
indicates its significant action of neurological performances. When 
compared to other FABPs of the brain, FABP3 is found in its later 
development stage. It acts in the production of neurites and the 
maturation of synapses. Lower levels of FABP3 may be associated 
with some neurological disorders such as Down syndrome and 
Alzheimer’s disease, which are caused by deficiencies in signal 
transduction and alterations in membrane structure [17]. The role 
of FABP3 in cancer is not yet fully understood, there are debates on 
whether it promotes or suppresses cancer. Previous studies found 
that FABP3 was overexpressed in 4 types of cancers: non-small 
cell lung carcinoma [18], gastric cancer [19], leiomyosarcoma [20] 
and melanoma [21]. Conversely, FABP3 was found to facilitate the 
suppression of breast cancer [22, 23], lung adenocarcinoma [24], 
lymphomas [25], and embryonic cancers [18].
FABP4
FABP4 secretion leads to several physiological effects including 
greater glucose production in hepatic cells, augmented insulin 
secretion and reduced cardiomyocyte contraction [26, 27]. It 
was reported that FABP4 has a paracrine/endocrine signalling 
function; thus it acts on nearby or distant organs after it is released 
from adipose tissue to change metabolism and cell function [1]. 
Recent studies have revealed that FABP4 can participate in the 
elaboration of atherosclerosis in heart disease via inflammation 
and the accumulation of lipids in the macrophages or foam cells. 
A study on mice revealed that a more than 60% reduction in the 
blockage of coronary arteries is observed with the absence of both 
ApoE and FABP4 when compared to the absence of ApoE alone. 
This shows an important role of FABP4 in the development of 
atherosclerosis [28, 29]. A number of studies had demonstrated the 
involvement of FABP4 in the aggressiveness of various cancers such 
as prostate cancer [30], breast cancer [31], cholangiocarcinoma 
[32], glioblastoma [33], and leukaemia [32]. Recent evidence 
suggests that FABP4 can be used as a novel molecular marker for 
the investigation, prediction, and the monitoring of bladder cancer 
during therapy as well as a potential novel therapeutic target 
[34]. The role of FABP4 in the epithelial-mesenchymal transition 
(EMT) of cancer cells was reported. FABP4 overexpression has 
been correlated to EMT transition in cholangiocarcinoma [32] and 
cervical cancer [35]. 
FABP5
FABP5, also named E-FABP or PA-FABP, is a 15 kDa cytosolic 
protein, which binds with a high affinity to medium and long 
chain fatty acids. FABP5 has a wide range distribution in the 
body: epidermis, mammary gland, brain, liver, kidney, lung, 
adipocyte, macrophage, tongue, and testis [2, 4]. Like other FABP 
family members, it binds and traffics fatty acids, in addition to the 
keratinocyte differentiation. It was suggested that FABP5 may have 
an association with obesity, abnormal lipid and insulin levels [2, 36]. 
FABP5 is an anandamide transporter, and a FABP5 inhibitor was 
used to manipulate the brain anandamide levels and thus to produce 
analgesia effect [37, 38]. Although over-expression of FABP5 in some 
cancer cells was noticed long-time ago, the molecular identification 
and functional characterisation of FABP5 as a tumour-promoter and 
a metastasis-inducer were first confirmed in prostate and breast 
cancer cells [6, 39]. FABP5 is expressed in high level in cancer cells, 
contributing to the aggressive phenotypes of cancer, promoting 
proliferation, invasion, tumorigenicity and metastatic ability of the 
cancer cells. High level of FABP5 expression was also related to the 
resistance to therapy and poor prognosis in various cancers such as 
gastric cancer [19, 40], melanoma [41], cervical cancer [42], breast 
cancer [43], prostate cancer [6, 44, 45], cholangiocarcinoma [46], 
oral cancer [47] and HCC [44]. Amongst all different cancer types, 
the role of FABP5 in promoting prostate cancer was studied most. 
Numerous studies proved FABP5 promoted tumor invasiveness 
both in vitro and in vivo [1]. A cohort study reported expression of 
FABP5 in triple negative breast cancer, the high level was associated 
with aggressive disease and low survival. The authors hypothesized 
that FABP5 exerted its effects via altering extracellular matrix to 
allow the tumor cells invading nearby organs [43].
It was reported that significantly high FABP5 levels in both 
prostate cancer cells and prostate carcinoma tissues [48]. It was 
found that the increased FABP5 expression was significantly 
associated with reduced patient survival time. When the level 
of FABP5 was suppressed via RNAi in prostate cancer cells, their 
tumorigenicity and metastatic ability was greatly suppressed 
both in vitro and in vivo [49]. During the extensive studies on the 
molecular mechanisms involved in the malignancy-promoting role 
of FABP5, a novel signal transduction pathway initiated by the 
stimulation of fatty acids transported by FABP5 was discovered. 
The detailed route for this signal transduction pathway is like 
following: the increased level of FABP5 transports a large amount 
of fatty acids into the cytoplasm, and most of the fatty acids were 
used as new sources of energy supply for the cells, whereas some 
excessive amount of fatty acids was delivered to their nuclear 
receptor PPARγ. The activated PPARγ can trigger a series of 
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molecular events or a chain of molecular reactions, including up-
regulating some cancer promoting genes, such as VEGF; and down-
regulating possible tumor-suppressor genes, and hence to facilitate 
the malignant progression of the cancer cells [50-53]. Recently, 
effort has been made for further exploring the FABP5-related signal 
transduction pathway in castration-resistant prostate cancer cells 
and for inhibiting the malignant progression of the cancer cells 
through targeting FABP5 [54]. 
FABP6
FABP6 is also known by its alternate name: intestinal bile acid 
binding protein and I-FABP, because of its high affinity for bile acid 
[55]. FABP6 is expressed mainly in the ileum, binding bile acid to 
give its major role as a surfactant to facilitate in lipid digestion, thus 
controlling bile acid and lipid homeostasis. The lack of expression 
of FABP6 in male mice renders them more susceptible to fatty liver 
disease [56]. Several attempts have been made to examine FABP6’s 
role in colorectal cancer. Since it is expressed widely in ileum, one 
study identified that FABP6 was highly expressed in colorectal 
carcinomas comparing to benign tissues. However, tissues from 
metastatic sites had low FABP6 levels [4]. Thus, more studies are 
required to determine the exact role of FABP6 in colorectal cancer 
and other cancer cells.
FABP7
FABP7 is expressed in glia cells of the nervous system [57], it 
was hypothesized that it contributes to central nervous system 
development by supplying fatty acids during cellular maturation 
[2]. One study suggested that FABP7 was associated with 
several psychiatric disorders, specifically, Down syndrome and 
schizophrenia [58]. More research is needed to understand its role. 
These neurological diseases may develop as a result of abnormal 
fatty acids binding and energy supply. FABP7 plays an important 
role in Notch1 signalling pathway. It has also been widely examined 
in breast cancer, in which a FABP7-positive cohort was associated 
with the triple negative breast cancer group. This correlated 
with poor survival outcome, high tumour grade and increased 
proliferation [59]. In 2008, Slipicevic et al. published a paper on 
melanoma in which they described a high expression of FABP7 
in both primary and metastatic tissues and the FABP7 level was 
correlated to increased tumour size and a decreased relapse-free 
survival period [4, 60]. However, the true role of FABP7 is not yet 
completed clear. 
FABP8
FABP8 is called myelin protein or M-FABP due to its 
predominance in peripheral nervous system myelin [61]. Despite 
decades of research, the role of M-FABP is unidentified; few 
studies had reported that it may be essential for myelin stabilizing 
and biogenesis [2, 62]. Until recently, there has been no reliable 
evidence of FABP8’s involvement in any types of carcinomas; more 
work is necessary to decide the role of FABP8 in cancer cells.
FABP9
It was proposed that FABP9 is one of major protein components 
of mammalian sperm [63]; it was assumed that it attributes to 
sperm protection [2, 64], however more studies are needed to 
understand its exact role. 
The possible involvement of FABP9 in prostate cancer was 
assessed in 2016 [65]. It was reported that FABP9 is overexpressed 
in both prostate cancer cells and tissues. This expression was 
correlated with increased malignancy and poor patient survival 
time. Thus, it is suggested that FABP9 could be bio-marker for 
predicting tumour malignancy and patient outcome, with a similar 
reliability with the combined Gleason scores. When FABP9 mRNA 
was knocked down by RNA interference and tested in vitro, it was 
suggested that the suppression of FABP9 expression produced 
significant inhibition on invasiveness of the cancer cells, but it 
did not seem to have significantly affected the cell proliferation, 
anchorage-independent growth which is an indication of 
tumorigenicity, and the migration rate [65]. More investigation is 
needed to decide whether FABP9 has a promotive role in cancer.
FABP12
It is the most recently discovered member of FABP family, 
little information is currently available, and it was detected in 
high level in human retinoblastoma cells [8]. FABP12 expression 
at both mRNA and protein levels were increased in malignant 
cell lines and the FABP12 increase is closely associated with 
increasing degree of malignancy. FABP12 was barely detectable in 
BPH, but its immunohistological staining in prostate carcinomas 
was significantly stronger than that in BPH. The staining intensity 
was increased as the increasing combined Gleason scores and the 
increased FABP12 is significantly associated with patient survival. 
Therefore, FABP12 may play an important promoting role in 
malignant progression of prostate cancer [66].
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